Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT)
-
- STATUS
- Recruiting
-
- End date
- Jun 13, 2021
-
- participants needed
- 300
-
- sponsor
- Blue Earth Diagnostics
Updated on 17 January 2021
Jingke Yang, MD
Primary Contact
Chesapeake Urology Research Associates (7.6 mi away) Contact
+30 other locationprostatectomy
prostate specific antigen
adenocarcinoma
adenocarcinoma of prostate
Summary
A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) ligand in men with suspected prostate cancer recurrence based on elevated Prostate-specific antigen (PSA) following prior therapy.
Details
| Treatment | rhPSMA-7.3 (18F) Injection |
|---|---|
| Clinical Study Identifier | NCT04186845 |
| Sponsor | Blue Earth Diagnostics |
| Last Modified on | 17 January 2021 |
How clear was the trial content above?
Hard
Easy
Adding a note
Select a piece of text and start making personal notes.
Similar trials to consider
Loading...
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer